Deciphera Pharmaceuticals Inc (OQ:DCPH)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 200 Smith St
WALTHAM MA 02451-0099
Tel: 1-212-6001902
IR: See website
Key People
James Arthur Bristol
Independent Chairman of the Board
Steven L. Hoerter
President, Chief Executive Officer, Director
Daniel Lee Flynn
Founder, Executive Vice President, Chief Scientific Officer
Thomas J. Kelly
Chief Financial Officer, Executive Vice President, Treasurer
Matthew L. Sherman
Executive Vice President, Chief Medical Officer
Business Overview
Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.
Financial Overview
For the six months ended 30 June 2020, Deciphera Pharmaceuticals Inc revenues decreased 71% to $7.2M. Net loss increased from $68.8M to $140M. Revenues reflect Collaboration revenues decrease of 91% to $2.3M. Higher net loss reflects Research and development - Balancing val increase of 63% to $88.9M (expense), General and administrative - Balancing v increase from $12.6M to $44.8M (expense).
Employees: 255 as of Feb 28, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $2,708M as of Jun 30, 2020
Annual revenue (TTM): $7.15M as of Jun 30, 2020
EBITDA (TTM): -$271.36M as of Jun 30, 2020
Net annual income (TTM): -$263.46M as of Jun 30, 2020
Free cash flow (TTM): -$228.58M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 56,376,754 as of Jul 31, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.